Not Yet Recruiting PHASE3 INTERVENTIONAL 3-arm NCT07279688

Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica (JADORE-BARI)

Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica - JADORE-BARI Study

Sponsor: Eli Lilly and Company

Conditions Polymyalgia Rheumatica (PMR)

Interventions Baricitinib 2 MG Oral Tablet Baricitinib 4 MG Oral Tablet Placebo 2 mg Placebo 4 mg

Updated 1 time since 2026 Last updated: Dec 11, 2025 Started: Dec 12, 2025 Primary completion: Nov 12, 2028 Completion: Jun 12, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07279688, this PHASE3 trial focuses on Polymyalgia Rheumatica (PMR) and remains actively recruiting participants. Sponsored by Eli Lilly and Company, it has been updated 1 time since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

1 version recorded

Not Yet Recruiting — PHASE3 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company
University Hospital, Brest

Data source: University Hospital, Brest

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aix-en-Provence, France , Arras, France , Besançon, France , Bordeaux, France , Brest, France , Caen, France , Cholet, France , Clermont-Ferrand, France , Dijon, France , Le Kremlin-Bicêtre, France and 10 more locations